Xbrane Biopharma Q2 2023: A setback but not case altering

Research Update



Redeye considers Xbrane’s Q2 weak due to slower sales ramp-up than anticipated and postponed profitability. We lower our fair value range but the drastic 43% drop observed yesterday reflects an excessively pessimistic and short-term perspective on the company.


Filip Einarsson

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.